388
Participants
Start Date
August 24, 2020
Primary Completion Date
July 30, 2024
Study Completion Date
July 30, 2024
PRV-015
Fully human monoclonal antibody against interleukin 15 (IL-15)
Placebo
Placebo
Clinical Trial Site, New York
Clinical Trial Site, Brooklyn
Clinical Site, New Windsor
Clinical Site, Uniontown
Clinical Trial Site, Girona
Clinical Site, Philadelphia
Clinical Trial Site, Chevy Chase
Clinical Site, León
Clinical Trial Site, Lleida
Clinical Site, Raleigh
Clinical Site, Madrid
Clinical Site, Madrid
Clinical Site, Madrid
Clinical Trial Site, North Charleston
Clinical Site, Winter Park
Clinical Site, Tampa
Clinical Site, Leesburg
Clinical Site, Nashville
Clinical Site, Seville
Clinical Trial Site, Dublin
Clinical Site, Chesterfield
Clinical Site, Rochester
Clinical Trial Site, Northbrook
Clinical Site, Chicago
Clinical Site, Garland
Clinical Trial Site, Cedar Park
Clinical Site, Denver
Clinical Site, West Jordan
Clinical Site, Los Angeles
Clinical Site, Ventura
Clinical Site, Bellevue
Clinical Site, Tacoma
Clinical Site, Boston
Clinical Site, Morristown
Clinical Site, Warwick
Clinical Site, Hamilton
Clinical Site, Amsterdam
Clinical Trial Site, Terrassa
Provention Bio, a Sanofi Company
INDUSTRY